Expression of C-terminal deleted p53 isoforms in neuroblastoma.
about
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsChd5 requires PHD-mediated histone 3 binding for tumor suppressionAntagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIMRUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenograftsp53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genesComplex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.p53 and its isoforms in cancerp53 and little brother p53/47: linking IRES activities with protein functions.The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.Peroxisome proliferator-activated receptor-β/δ inhibits human neuroblastoma cell tumorigenesis by inducing p53- and SOX2-mediated cell differentiation.Expression of p53β and Δ133p53 isoforms in different gastric tissues.Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma.Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis.Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.The p53 isoforms are differentially modified by Mdm2.SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cellsp53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Identification of nonsense-mediated mRNA decay pathway as a critical regulator of p53 isoform β.Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway.Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.
P2860
Q27670943-5C893694-0B22-4CBB-9A0D-2A33FDC775D7Q28593132-0FB46ACB-A56C-4AC4-8108-6AC4B8735523Q33336561-0F5B18D3-B511-473B-9674-54B372C33422Q33883483-47D4E97E-41D7-43FE-A65A-3C6EFEF34ABAQ35013107-43968016-D620-40EC-895A-F6D25C4FADAAQ36052576-F6E613B4-11DC-47B3-95A6-F3BA3E675E2FQ36742203-C54D7D51-AF79-41BB-A52B-810581E72F75Q36885363-BFBE1747-3F6F-4C95-8953-197294292657Q37502697-AAD58CD0-E849-4267-96E9-CB74C59AEBF3Q37701672-B0D727ED-EFF9-4DFD-AA96-0822F32155BEQ38725289-465DD9AD-3928-4B56-B4FE-A60F2C92AFA6Q38815869-30B314BC-7BF8-4763-B1AC-743FF6D475B1Q38913917-E3A23DA4-E6C9-4BD5-9C7A-E97434A2C903Q38923189-80000E18-DF78-49F5-843C-AC262DDB9F3FQ38985584-63DD93FB-3B06-4DAF-BE70-319800226061Q39016943-5490040C-9446-4278-BB40-B5731AC23DDBQ39068591-4106C4B7-C160-4535-8FE9-D4555940055CQ39236844-C270EC1A-1994-4638-BCB2-AF9C7C557979Q39317407-20B4F41D-4549-4E65-BAA2-B4CD20FE16B0Q39367419-058713E7-B55E-47C0-BD69-16FAB97D5687Q39562657-0CBB51B0-A36E-4A4D-8480-2F927A83F49DQ39620511-CDA19D13-D7D7-414D-8669-FA13CFEAD424Q39655015-FB849AC6-8910-468C-AF8B-7FB1E25EF7AEQ41840140-0EF857A3-BF0B-40B4-BC48-E3CFC55EBE1DQ41869723-BB4BD8F3-E31F-4BFE-94C0-4A7DDA2CD2A7Q42160338-A2AD8EB6-8726-472C-85ED-E10917419E03Q42362115-2530C458-9D63-4393-8615-2526FBB1E57DQ47131765-35AE833A-FEAC-4A08-8695-69E1A4371C90Q47142941-D3D4DD8A-FE49-424E-8335-0B7B3A378A57Q48725316-B2CCC325-CE1C-4F13-BD7A-0277EAD109C0
P2860
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@ast
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@en
type
label
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@ast
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@en
prefLabel
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@ast
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@en
P2093
P2860
P356
P1476
Expression of C-terminal deleted p53 isoforms in neuroblastoma.
@en
P2093
David Goldschneider
Emilie Horvilleur
Evelyne May
Evelyne Wittmer-Dupret
Gisèle Danglot
Hughes de Thé
Jean Bénard
Karine Million
Louis-François Plassa
P2860
P304
P356
10.1093/NAR/GKL619
P407
P577
2006-10-05T00:00:00Z